Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw

Oncologist

Volumn 16, Issue 1, 2011, Pages 121-132

  Miksad, Rebecca Anne ^a,b,c,d   Lai, Kuan Chi ^a,c,d   Dodson, Thomas Benton ^d,e   WOO, Sook Bin ^e,f   Treister, Nathaniel Simon ^e,f   Akinyemi, Omosalewa ^c,d   Bihrle, Marian ^a,c,d   Maytal, Guy ^d,e   August, Meredith ^d,e   Scott Gazelle, G ^b,c,d   Shannon Swan, J ^b,c,d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Institute for Technology Assessment   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bisphosphonates; Osteonecrosis; Pamidronate; Quality of life; Utility; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ANXIETY; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; FEEDING BEHAVIOR; FEMALE; HUMAN; IRRITABILITY; JAW OSTEONECROSIS; LIFE SATISFACTION; LUNG CANCER; MALE; MULTIPLE MYELOMA; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RETROSPECTIVE STUDY; SCORING SYSTEM; VISUAL ANALOG SCALE;

BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DIPHOSPHONATES; FEMALE; HUMANS; JAW; JAW DISEASES; MALE; MIDDLE AGED; OSTEONECROSIS; QUALITY OF LIFE;

EID: 79952590281     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0183     Document Type: Article

References (118)

1. Gutta R, Louis PJ. Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104(2):186-193.
2. Hewitt C, Farah CS. Bisphosphonate-related osteonecrosis of the jaws: acomprehensive review. J Oral Pathol Med 2007;36(6):319-328.
3. Lam DK, Sandor GK, Holmes HI et al. A review of bisphosphonateassociated osteonecrosis of the jaws and its management. J Can Dent Assoc 2007;73(5):417-422.
4. Mariotti A. Bisphosphonates and osteonecrosis of the jaws. J Dent Educ 2008;72(8):919-929.
5. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7(6):508-514.
6. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaws. CompendContin Educ Dent 2008;29(2):96-98, 100-102, 104-105.
7. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102(4):433-441.
8. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144(10): 753-761.
9. Wilkinson GS, Kuo YF, Freeman JL et al. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a populationbased analysis. J Natl Cancer Inst 2007;99(13):1016-1024.
10. In re Fosamax Products Liability Litigation (No. 1:06-MD-1789, S.D.N.Y.).
11. In re Aredia and Zometa Products Liability Litigation (No. 3:06-MD-7160, M.D. Tenn.).
12. Barker K, Lowe D, Olujohungbe A et al. Survey of members of myeloma U.K. on biphosphonates-associated jaw osteonecrosis. Br J Haematol 2007;139(4):626-628.
13. Hoff AO, Toth BB, Altundag K et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenousbisphosphonates. J Bone Miner Res 2008;23(6):826-836.
14. Wang EP, Kaban LB, Strewler GJ et al. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007;65(7): 1328-1331.
15. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353(1);99-102, 2005; discussion 199-102.
16. Zervas K, Verrou E, Teleioudis Z et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a singlecentre experience in 303 patients. Br J Haematol 2006;134(6):620-623.
17. Boonyapakorn T, Schirmer I, Reichart PA et al. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008;44(9):857-869.
18. Ortega C, Montemurro F, Faggiuolo R et al. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. Acta Oncol 2007;46(5):664-668.
19. Fehm T, Beck V, Banys M et al. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol 2009;112(3):605-609.
20. Jadu F, Lee L, Pharoah M et al. Aretrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 2007;18(12):2015-2019.
21. Walter C, Grotz KA, Kunkel M et al. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer 2007;15(2):197-202.
22. Mavrokokki T, Cheng A, Stein B et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007;65(3):415-423.
23. Ibrahim T, Barbanti F, Giorgio-Marrano G et al. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study. The Oncologist 2008;13(3):330-336.
24. Murad OM, Arora S, Farag AF et al. Bisphosphonates and osteonecrosis of the jaw: a retrospective study. Endocr Pract 2007;13(3):232-238.
25. Dodson TB. Intravenous bisphosphonate therapy and bisphosphonaterelated osteonecrosis of the jaws. J Oral Maxillofac Surg 2009;67(5 Suppl):44-52.
26. Tosi P, Zamagni E, Cangini D et al. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood 2006;108(12):3951-3952.
27. Barasch A. Clinical, Pharmacological, and Biological Issues in ONJ. Paper presented at: American Association for Dental Research 38th Annual Meeting; March 3-6, 2010, Washington, DC.
28. Curro FA. Findings of the CONDOR Case-Control Study of ONJ. Paper presented at: American Association for Dental Research 38th Annual Meeting; March 3-6, 2010, Washington, DC.
29. Favia G, Pilolli GP, Maiorano E. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients. J Rheumatol 2009;36(12):2780-2787.
30. FDA. Actonel Label Prescribing Information, 2009.
31. FDA. Boniva Label Prescribing Information, 2010.
32. FDA. Fosamax Label Prescribing Information, 2010.
33. Fellows JL, Rindal DB, Barasch A et al. PS1-31: osteonecrosis of the jaw in two dental PBRN health plans. Clin Med Res 2010;8:42.
34. Hujoel P. Design of the CONDOR Case-Control Study of ONJ. Paper presented at: American Association for Dental Research 38th Annual Meeting; March 3-6, 2010, Washington, DC.
35. Lo JC, O'Ryan FS, Gordon NP et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010;68(2):243-253.
36. FDA. Prescription Drug User Fee Act (PDUFA) IV Drug Safety Five-Year Plan 2008-2012. Available at http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM119244.pdf.Accessed May 17, 2010.
37. Giordano SH, Fang S, Duan Z et al. Use of intravenous bisphosphonates in older women with breast cancer. The Oncologist 2008;13(5):494-502.
38. Novartis. Product Sales. Available at http://www.novartis.com/investors/salesresults/product-sales.shtml. Accessed May 17, 2010.
39. Phase III Randomized Study of Adjuvant Zoledronate Versus Clodronate Versus Ibandronate in Women With Resected Primary Stage I-III Adenocarcinoma of the Breast. Available at http://www.cancer.gov/clinicaltrials/SWOG-S0307. Accessed January 10, 2010.
40. Brufsky A, Bundred N, Coleman R et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausalwomen with early breast cancer receiving adjuvant letrozole. The Oncologist 2008;13(5):503-514.
41. Safra T, Bernstein R, Stephansky I et al. Zolandronic acid protective effect on bone loss in postmenopausal women switched from tamoxifen to letrozolein the treatment of early breast cancer [abstract 1153]. Paper presented at: 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008, San Antonio, TX.
42. Gnant M, Mlineritsch B, Schippinger W et al. Endocrine therapy pluszoledronic acid in premenopausal breast cancer. N Engl J Med 2009; 360(7):679-691.
43. Hershman DL, McMahon DJ, Crew KD et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008;26(29):4739-4745.
44. Wardley A, Davidson N, Barrett-Lee P et al. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bonemetastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br J Cancer 2005;92(10):1869-1876.
45. Fuleihan Gel H, Salamoun M, Mourad YA et al. Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal womenwith breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 2005;90(6):3209-3214.
46. Saarto T, Blomqvist C, Valimaki M et al. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer 1997;75(4):602-605.
47. Rosen LS, Gordon D, Tchekmedyian S et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancerand other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21(16):3150-3157.
48. Ficarra G, Beninati F, Rubino I et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J Clin Periodontol 2005;32(11):1123-1128.
49. Merigo E, Manfredi M, Meleti M et al. Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronateand zoledronate): a four-case report. J Oral Pathol Med 2005; 34(10):613-617.
50. Mignogna MD, Fedele S, Lo Russo L et al. Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy. J Clin Oncol 2006;24(9): 1475-1477.
51. Vannucchi AM, Ficarra G, Antonioli E et al. Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br JHaematol 2005;128(6):738.
52. Atchison KA, Gironda MW, Black EE et al. Baseline characteristics and treatment preferences of oral surgery patients. J Oral Maxillofac Surg 2007;65(12):2430-2437.
53. Thierer T, Friedman B. Preferences for oral health states in a US community-dwelling functionally impaired older adult population: 2000-2001. J Public Health Dent 2006;66(4):248-254.
54. Nassani MZ, Devlin H, McCord JF et al. The shortened dental arch-an assessment of patients' dental health state utility values. Int Dent J 2005; 55(5):307-312.
55. Mileman PA, van den Hout WB. Preferences for oral health states: effect on prescribing periapical radiographs. Dentomaxillofac Radiol 2003; 32(6):401-407.
56. Brickley M, Armstrong R, Shepherd J et al. The relevance of health state utilities to lower third molar surgery. Int Dent J 1995;45(2):124-128.
57. Rogers SN, Miller RD, Ali K et al. Patients' perceived health status followingprimary surgery for oral and oropharyngeal cancer. Int J Oral Maxillofac Surg 2006;35(10):913-919.
58. Ackerman SJ, Sullivan EM, Beusterien KM et al. Cost effectiveness of recombinant human insulin-like growth factor I therapy in patients with ALS. Pharmacoeconomics 1999;15(2):179-195.
59. Brown B, Diamantopoulos A, Bernier J et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health 2008;11(5):791-799.
60. Center for the Evaluation of Value and Risk in Health. The Cost-Effectiveness Analysis Registry. IfCRaHPS, Tufts Medical Center. Available at www.cearegistry.org. Accessed November 14, 2009.
61. Lloyd A, Nafees B, Narewska J et al. Health state utilities for metastatic breast cancer. Br J Cancer 2006;95(6):683-690.
62. Berenson JR, Hillner BE, Kyle RA et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002;20(17):3719-3736.
63. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21(21):4042-4057.
64. Khan AA, Sandor GK, Dore E et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008;35(7):1391-1397.
65. Ruggiero SL, Dodson TB, Assael LA et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009;67(5 Suppl):2-12.
66. Botteman M, Barghout V, Stephens J et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006;17(7):1072-1082.
67. Hillner BE, Weeks JC, Desch CE al. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol 2000;18(1):72-79.
68. Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28(35):5132-5139.
69. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65(3):369-376.
70. Miksad RA, Woo S, Dodson T et al. Quality of life implications of osteonecrosis of the jaw in cancer patients: a pilot study. J Clin Oncol 2008; 26(15 suppl):Abstract 17557.
71. Hunink M, Glasziou P, Siegel J et al. Valuing outcomes: Relationships among techniques for valuing outcomes. In: Decision Making in Health and Medicine: Integrating Evidence and Values. Cambridge, U.K.: Cambridge University Press, 2001:106-107.
72. Kind P. The EuroQol Instrument: An Index of Health Related Quality of Life. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Second Edition. Philadelphia: Lippincott-Raven Publishers, 1996:191-201.
73. Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med Decis Making 2001;21(4):329-334.
74. Torrance GW, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programs. Health Serv Res 1972;7(2):118-133.
75. Furlong W, Feeny D, Torrance GW et al. Guide to Design and Development of Health-State Utility Instrumentation. McMaster University CHEPA Working Paper Series. 1990. Paper 90-99. Cited with permission.
76. Drummond MF, Sculpher MJ, Torrance GW et al. Cost-utility analysis: Measuring preferences. In: Methods for the Economic Evaluation of Health Care Programmes. Third Edition. New York: Oxford University Press, 2005;147-154.
77. Froberg DG, Kane RL. Methodology for measuring health-state preferences-II: Scaling methods. J Clin Epidemiol 1989;42(5):459-471.
78. Krabbe PF, Essink-Bot ML, Bonsel GJ. The comparability and reliability of five health-state valuation methods. Soc Sci Med 1997;45(11):1641-1652.
79. Calculating the U.S. Population-based EQ-5D Index Score. August 2005. Agency for Healthcare Research and Quality, Rockville, MD. Available at http://www.ahrq.gov/rice/EQ5Dscore.htm. Accessed November 13, 2008.
80. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005; 43(3):203-220.
81. Slade GD. Derivation and validation of a short-form oral health impact profile. Community Dent Oral Epidemiol 1997;25(4):284-290.
82. Robinson PG, Gibson B, Khan FA et al. Validity of two oral health-related quality of life measures. Community Dent Oral Epidemiol 2003;31(2): 90-99.
83. Allen PF, Locker D. Do item weights matter? An assessment using the oral health impact profile. Community Dent Health 1997;14(3):133-138.
84. Soe KK, Gelbier S, Robinson PG. Reliability and validity of two oral health related quality of life measures in Myanmar adolescents. Community Dent Health 2004;21(4):306-311.
85. Locker D. Measuring oral health: a conceptual framework. Community Dent Health 1988;5(1):3-18.
86. Baker SR, Pankhurst CL, Robinson PG. Utility of two oral health-related quality-of-life measures in patients with xerostomia. Community Dent Oral Epidemiol 2006;34(5):351-362.
87. Gold MR, Patrick DL, Torrance GW et al. Identifying and Valuing Outcomes. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost Effectiveness in Health and Medicine. Oxford, U.K.: Oxford University Press, 1996;82-134.
88. Stein K, Fry A, Round A et al. What value health?:Areview of health state values used in early technology assessments for NICE. Appl Health Econ Health Policy 2005;4(4):219-228.
89. Bennett KJ, Torrance GW. Measuring Health State Preferences and Utilities: Rating Scale, Time Trade-Off, and Standard Gamble Techniques. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Second Edition. Philadelphia: Lippincott-Raven Publishers, 1996:253-265.
90. Green C, Brazier J, Deverill M. Valuing health-related quality of life. A review of health state valuation techniques. Pharmacoeconomics 2000; 17(2):151-165.
91. Akbari M, Miksad RA, Weinstein MC. The Role of Bisphosphonate Therapy in Multiple Myeloma Patients: A perspective on Osteonecrosis of the Jaw and Quality of Life. Paper presented at: 30th Annual Meeting of the Society for Medical Decision Making; 2008.
92. Greipp PR, San Miguel J, Durie BG et al. International staging system for multiple myeloma. J Clin Oncol 2005;23(15):3412-3420.
93. Woodward WA, Strom EA, Tucker SL et al. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 2003;21(17):3244-3248.
94. Fryback DG, Lawrence WF Jr. Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments. Med Decis Making 1997;17(3):276-284.
95. Galea S, Nandi A, Stuber J et al. Participant reactions to survey research in the general population after terrorist attacks. J Trauma Stress 2005;18(5): 461-465.
96. SAS software, Version 9.1 of the SAS System for Windows. Copyright 2002-2003 SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA.
97. von Elm E, Altman DG, Egger M et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147(8):573-577.
98. Tosteson AN, Gabriel SE, Grove MR et al. Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 2001;12(12); 1042-1049.
99. Stewart ST, Lenert L, Bhatnagar V et al. Utilities for prostate cancer health states in men aged 60 and older. Med Care 2005;43(4):347-355.
100. Loeb S, Roehl KA, Helfand BT et al. Complications of open radical retropubic prostatectomy in potential candidates for active monitoring. Urology 2008;72(4):887-891.
101. Potosky AL, Legler J, Albertsen PC et al. Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000;92(19):1582-1592.
102. The Standards for Educational and Psychological Testing. Second Edition. Washington, DC: American Educational Research Association, 1999.
103. Solomayer E, Gebauer G, Hirnle P et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients [abstract 2048]. Paper presented at: 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008, San Antonio, TX.
104. Winter M, Thorpe H, Burkinshaw R et al. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response exploratory evidence for direct anti-tumor activity in breast cancer [abstract 5101]. Paper presented at: 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008, San Antonio, TX.
105. Edwards BJ, Hellstein JW, Jacobsen PL et al. Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy: an advisory statement from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc 2008;139(12):1674-1677.
106. Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone. Available at http://www.clinicaltrials.gov/ct2/show/NCT00458796?term_NCT00458796&rank_1. Accessed January 10, 2010.
107. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 2008;66(4):625-631.
108. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18(2):75-85.
109. Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23(34):8580-8587.
110. Dimopoulos MA, Kastritis E, Anagnostopoulos A et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91(7):968-971.
111. Dimopoulos MA, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20(1):117-120.
112. Ripamonti CI, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009;20(1):137-145.
113. Havrilesky LJ, Broadwater G, DavisDMet al. Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol Oncol 2009;113(2):216-220.
114. Bartoces MG, Severson RK, Rusin BA et al. Quality of life and selfesteem of long-term survivors of invasive and noninvasive cervical cancer. J Womens Health (Larchmt) 2009;18(5):655-661.
115. Palaska PK, Cartsos V, Zavras AI. Bisphosphonates and time to osteonecrosis development. The Oncologist 2009;14(11):1154-1166.
116. Earle CC, Chapman RH, Baker CS et al. Systematic overview of costutility assessments in oncology. J Clin Oncol 2000;18(18):3302-3317.
117. Lidgren M, Wilking N, Jonsson B et al. Health related quality of life in different states of breast cancer. Qual Life Res 2007;16(6):1073-1081.
118. Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000;38(6):583-637